Navigation Links
Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
Date:11/27/2011

he treatment of individuals with inhibitor complications.  Inspiration has a broad portfolio of recombinant hemophilia products, which includes two products in late-stage clinical development and two preclinical programs.

Inspiration's two lead programs are IB1001, an intravenous recombinant factor IX (FIX) product being developed for the treatment and prevention of bleeding in individuals with hemophilia B, and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product being developed for the treatment of individuals with congenital hemophilia A who have inhibitors against human FVIII and for individuals with acquired hemophilia A.  Inspiration recently submitted its first marketing application for IB1001 in Europe, with a subsequent regulatory filing planned in the U.S in the first half of 2012.  Earlier-stage preclinical programs at Inspiration are focused on human recombinant factor VIIa (FVIIa), for individuals with either hemophilia A or hemophilia B who have developed inhibitors, and for individuals with factor VII deficiency; and human recombinant FVIII, to treat individuals with hemophilia A.

Inspiration has extensive expertise and experience in hemophilia product development, biologics manufacturing, regulatory approval and global commercialization.  The Company's senior leadership was directly responsible for the development and commercialization of the majority of hemophilia products currently on the market.

In addition, in January 2010, Inspiration entered into a strategic partnership with the Ipsen Group (EURONEXT: IPN; ADR: IPSEY), leveraging the combined expertise and resources of the two companies, to develop a broad portfolio of hemophilia products.  As announced in late August 2011, Ipsen and Inspiration extended their partnership to create a hemophilia business unit structure that will act as the exclusive sales organization for all hemophilia products commercialized under the Inspiration b
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Inspiration for My Sisters Keeper Speaks Out
4. National Expressions of Courage Art Contest Unveils Stories of Inspiration
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
8. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
9. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
10. Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
11. Heskas 2011 "Inspiration in Action" Contest Begins: Support the Veterinary Profession and Help Animals in Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... BEIJING, May 6, 2015 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in China, today ... of 2015. First Quarter 2015 Financial ... quarter of 2015 increased by 25.0% to $70.4 million ... , Gross profit increased by 18.9% to $45.9 ...
(Date:5/6/2015)... May 6, 2015 Asterias Biotherapeutics, Inc. ... the emerging field of regenerative medicine, today announced ... the investment community to review the clinical development ... cord injury on Friday, May 8, 2015. Topics ... and future planned clinical activities for AST-OPC1. ...
(Date:5/6/2015)... -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today ... 2015.  The net loss and the loss from operations ... million, respectively, compared to $10.7 million and $8.8 million ... 31, 2015, Alexza had consolidated cash, cash equivalents, marketable ... "We continue to focus on ways in which to ...
Breaking Medicine Technology:China Biologic Reports Financial Results for the First Quarter of 2015 2China Biologic Reports Financial Results for the First Quarter of 2015 3China Biologic Reports Financial Results for the First Quarter of 2015 4China Biologic Reports Financial Results for the First Quarter of 2015 5China Biologic Reports Financial Results for the First Quarter of 2015 6China Biologic Reports Financial Results for the First Quarter of 2015 7China Biologic Reports Financial Results for the First Quarter of 2015 8China Biologic Reports Financial Results for the First Quarter of 2015 9China Biologic Reports Financial Results for the First Quarter of 2015 10China Biologic Reports Financial Results for the First Quarter of 2015 11China Biologic Reports Financial Results for the First Quarter of 2015 12China Biologic Reports Financial Results for the First Quarter of 2015 13China Biologic Reports Financial Results for the First Quarter of 2015 14China Biologic Reports Financial Results for the First Quarter of 2015 15China Biologic Reports Financial Results for the First Quarter of 2015 16China Biologic Reports Financial Results for the First Quarter of 2015 17China Biologic Reports Financial Results for the First Quarter of 2015 18Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 2Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 3Alexza Reports 2015 First Quarter Financial Results 2Alexza Reports 2015 First Quarter Financial Results 3Alexza Reports 2015 First Quarter Financial Results 4Alexza Reports 2015 First Quarter Financial Results 5Alexza Reports 2015 First Quarter Financial Results 6Alexza Reports 2015 First Quarter Financial Results 7Alexza Reports 2015 First Quarter Financial Results 8Alexza Reports 2015 First Quarter Financial Results 9Alexza Reports 2015 First Quarter Financial Results 10
... announced today the successful submission of an IND application ... clinical trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ... first quarter of 2009. IQP-0410 is a novel small ... nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a ...
... from prior U.S., U.K. and China TrialsSAN DIEGO, Jan. ... company targeting liver disease, today announced patient enrollment has ... trial that will study the Extracorporeal Liver Assist Device ... Failure (ALF) under three protocols. The study is open ...
Cached Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3
(Date:5/6/2015)... VA (PRWEB) May 07, 2015 Device Patent ... 27, 2015 — 11:00 a.m. – 12:30 p.m. EDT, ... up in expensive patent lawsuits and claims that waste their ... Many of these cases could be prevented if devicemakers better ... the latest court rulings and revisions to patent laws from ...
(Date:5/6/2015)... 06, 2015 RPS Revolution - a game ... tried and true Rock Paper Scissors game - is now ... that encourage storytelling and easy to learn rules from Rock ... an old favorite. RPS Revolution takes the best ... characters that are grouped in set of three called Trios. ...
(Date:5/6/2015)... May 06, 2015 Imprivata ® ... that CTO David Ting will lead a discussion about ... data security and user authentication challenges, during Citrix ... session will focus on the benefits of creating a ... care providers and patients can share information. It will ...
(Date:5/6/2015)... Qushanna Doby (20) was arrested for child neglect, after leaving ... while under the influence of Flakka, according to CBS ... CBS4’s Peter D’Oench records Doby distraught in a parking lot ... year old. The drug treatment center in Florida who found ... residents polled by CBS Miami express concern about the fate ...
(Date:5/6/2015)... May 06, 2015 The Canton Group is ... for the 6th annual charity softball game. The event ... & T Bank Stadium. Past years guests include Joe Flacco, ... are still on sale if you are interested ... local non-profit organizations, such as SOAR Baltimore and ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 2Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 3Health News:RPS Revolution Launches Kickstarter Campaign 2Health News:RPS Revolution Launches Kickstarter Campaign 3Health News:Imprivata to Lead Discussion about Patient and Provider Authentication Challenges and the Internet of Things in Healthcare during Citrix Synergy 2Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 3
... the opposite sex is looking at you depends on how masculine ... speculate that there may be an evolutionary advantage to quickly noticing ... how we determine whether someone else is looking at us or ... problem," says Benedict C. Jones, of the University of Aberdeen in ...
... gas bubbles and sound waves is to be developed at ... drugs to be delivered in small doses directly to tumours, ... If successful, the technique could easily be adapted for other ... cancer specialists from across the University to work on the ...
... the Iacocca Foundation announce today the completion of the Phase ... as the submission of all safety reports to the U.S. ... monitoring boards. Plans for the Phase II clinical study, which ... a treatment for people with existing type 1 diabetes, are ...
... ... as series co-host , ... Alpharetta, GA (Vocus) June 28, 2010 -- Physician recruiting firm LocumTenens.com ... channel for medical professionals broadcast on XM Satellite Radio channel 160, ReachMD.com, and the ...
... ... its effect on losing weight. It looks at how ephedrine products affect the body,s energy ... ... of an article that examines ephedrine HCL and its effects on weight loss. This article, ...
... Shopping for life insurance ... that matches their needs and stay within their budget., , ... Miami, Florida (PRWEB) June 28, 2010 -- An online life insurance firm is ... to pay for a term life insurance policy. With the introduction of the Select Your ...
Cached Medicine News:Health News:Reading the look of love 2Health News:Bursting bubbles with sound offers new treatments for cancer 2Health News:Bursting bubbles with sound offers new treatments for cancer 3Health News:Mass. General Hospital, Iacocca Foundation announce completion of Phase I diabetes trial 2Health News:LocumTenens.com to Sponsor New Series, Your Career In Healthcare, on ReachMD XM 160 2Health News:New Article Re-Examines Ephedrine HCL Products For Weight Loss 2Health News:Online Broker Lets Consumers Choose The Price of Life Insurance 2Health News:Online Broker Lets Consumers Choose The Price of Life Insurance 3
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection Tubes ... Available for a wide range of applications, ... a capillary tube, attached cap and a ... to draw the blood into the micro ...
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection ... systems. Available for a wide range of ... with a capillary tube, attached cap and ... action to draw the blood into the ...
... serology for Toxoplasmosis has progressed ... specialized dye test to immunoflourescence, ... techniques. In addition to ... offers both Toxo IgM immunocapture ...
Serology provides a minimally-invasive, sensitive and easy-to-perform method for the determination of H. pylori infection. The Bio-Rad H. pylori qualitative test kits use EIA technology for the deter...
Medicine Products: